PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 29, 2024Journal of drug targeting5 citationsOpen Access

Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer

View Full Paper
YTYiran TaoYLYing LuTXTing Xue

Key Points

Key points are not available for this paper at this time.

Abstract

Antibody-drug conjugates (ADCs) have emerged as a novel class of targeted cancer therapies and been successfully applied in the treatment of breast cancer (BC). Discoidin domain receptor 1 (DDR1) is a single transmembrane receptor tyrosine kinase and has been identified as a possible target for cancer. In this study, we explored the potential of an anti-DDR1 ADC, named T

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tao et al. (2024) studied this question.

synapsesocial.com/papers/68e5ea38b6db64358757ef63https://doi.org/10.1080/1061186x.2024.2386621
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison between NOD/SCID mice and BALB/c mice for patient-derived tumor xenografts model of non-small-cell lung cancer2018 · 14 citations
  2. 2New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development2022 · 33 citations
  3. 3Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab’-Immunoliposomes for Gene Silencing in Breast Cancer Cells2020 · 32 citations
  4. 4DDR1 and MT1-MMP Expression Levels Are Determinant for Triggering BIK-Mediated Apoptosis by 3D Type I Collagen Matrix in Invasive Basal-Like Breast Carcinoma Cells2019 · 37 citations
  5. 5Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer2014 · 544 citations